RBC Capital Downgrades OncoGenex Pharmaceuticals (OGXI) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- Nasdaq slides to near one-month low as AI rout deepens
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts OGXI Hot Sheet
Price: $0.40 --0%
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 10 | New: 31
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 10 | New: 31
Join SI Premium – FREE
RBC Capital downgraded OncoGenex Pharmaceuticals (NASDAQ: OGXI) from Outperform to Sector Perform with a price target of $4.50 (from $19.00).
For an analyst ratings summary and ratings history on OncoGenex Pharmaceuticals click here. For more ratings news on OncoGenex Pharmaceuticals click here.
Shares of OncoGenex Pharmaceuticals closed at $3.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Upgrades JCDecaux SA (DEC:FP) (JCDXF) to Buy
- Canadian National Railway (CNR:CN) (CNI) PT Lowered to Cdn$198 at Scotiabank
- KION Group AG (KGX:GR) (KIGRY) PT Lowered to EUR52 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
